查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1643910

全球组织工程市场 - 2025-2033

Global Tissue Engineering Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

全球组织工程市场在2024年达到189亿美元，预计2033年将达到651亿美元，2025-2033年预测期间复合年增长率为14.9%。

组织工程是了解某些疾病如何进展以及如何治疗的重要工具。它是生物工程领域的一部分，生物工程是一门结合了生物学和工程学原理的广泛学科。生物工程有时被描述为采用工程方法来研究生物学。组织工程涉及研究组织发育、损伤和伤口癒合中涉及的生物、物理和化学力。

组织工程的目标是製造能够与患者身体无缝整合的功能性组织和器官，最终改善患者的治疗结果和生活品质。该领域涵盖各种方法，包括基于支架的技术、基于细胞的疗法和生物活性分子递送系统。

随着组织工程领域的进步和组织工程资金的增加，组织工程市场正在经历持续成长。例如，2023 年 11 月，SPRIND Funke Tissue Engineering 与四个雄心勃勃的团队启动了为期十个月的旅程，探索和展示人造组织的关键特性。 SPRIND 提供了高达 50 万欧元的资金来支持这项开创性的工作。

市场动态：

驱动程式和限制

慢性病盛行率上升

慢性病盛行率的上升极大地推动了组织工程市场的成长，预计将在预测期内推动该市场的成长。随着糖尿病、心血管疾病、骨关节炎和肾臟疾病等慢性疾病在全球的增加，对包括组织工程在内的先进治疗方案的需求也在增加。

例如，根据世界卫生组织统计，每年估计有 1790 万人死于心血管疾病 (CVD)，使其成为世界上最主要的死亡原因。全球 4.22 亿糖尿病患者中的大部分居住在低收入和中等收入国家，该疾病每年直接导致 150 万人死亡。全球约有 17.1 亿人患有肌肉骨骼疾病。由于多种慢性疾病发生率的上升，预计对组织工程的需求将会增加。

慢性疾病通常会导致传统治疗无法完全修復的组织损伤或退化。组织工程透过创造替代组织或器官来提供解决方案，帮助癒合和再生。例如，糖尿病患者的伤口癒合不良，需要组织工程来修復皮肤或血管。

此外，脑、肺、肝臟和骨组织工程的发展有助于创建癌症转移的体外模型。由于组织工程提供了直接检查癌症发生和转移灶迁移的方法，因此它有可能彻底改变癌症研究。由于诱导血管生成是癌症的关键特征，因此新血管形成通常与实体肿瘤的形成有关。此外，组织工程使得复製肿瘤微环境及其所有复杂和多方面的特征成为可能。因此，癌症病例的增加增加了对组织工程的需求。

与组织工程技术相关的高成本

与组织工程技术相关的高成本是阻碍组织工程市场成长的主要因素之一。虽然组织工程有望解决慢性疾病和组织损伤，但其开发、生产和实施所涉及的成本是巨大的。例如，根据美国国立卫生研究院 (NIH) 的数据，三名英国患者接受干细胞组织工程气道移植的总费用为 174,420 美元至 740,500 美元。

由于需要专门的生物列印机、先进的生物材料和熟练的技术人员，使用 3D 列印技术开发生物列印组织的成本非常高。儘管该技术具有巨大的潜力，但目前尚无法广泛使用。例如，据 ResearchGate 称，生物列印技术的价格从 5,000 美元到超过 50 万美元不等。

目录

第一章：市场介绍和范围

  • 报告的目标
  • 报告范围和定义
  • 报告范围

第 2 章：高阶主管见解与要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按材料类型分類的片段
  • 技术片段
  • 按应用程式片段
  • 最终使用者的片段
  • 按地区分類的片段

第 3 章：动力学

  • 影响因素
    • 司机
      • 慢性病盛行率上升
    • 限制
      • 与组织工程技术相关的高成本
    • 机会
    • 影响分析

第 4 章：策略洞察与产业展望

  • 市场领导者和先驱
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的知名领导者
    • 拥有成熟产品的市场领导者
  • 新兴新创企业和关键创新者
  • CXO 观点
  • 最新进展和突破
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • SWOT分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态

第 5 章：组织工程市场（依材料类型）

  • 合成材料
    • 聚合物
    • 水凝胶
    • 陶瓷
    • 复合材料
  • 天然材质
    • 细胞外基质 (ECM) 蛋白
    • 纤维蛋白
    • 胶原
    • 丝绸
  • 奈米纤维支架
  • 蛋白质基材料
  • 其他的

第 6 章：依技术分類的组织工程市场

  • 生物材料和支架
  • 细胞培养
  • 生物反应器和培养系统
  • 生物列印
  • 其他的

第 7 章：组织工程市场（按应用）

  • 肌肉骨骼
  • 皮肤和外皮
  • 心臟病学
  • 神经病学
  • 其他的

第 8 章：组织工程市场（依最终使用者）

  • 医院和诊所
  • 合约开发和製造组织
  • 研究和学术机构
  • 生物技术和製药公司

第 9 章：组织工程市场，按区域市场分析和成长机会

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 10 章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的主要发展
  • 公司基准化分析

第 11 章：公司简介

  • 3D BioFibR Inc.
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
    • SWOT分析
  • CollPlant Biotechnologies Ltd.
  • Lonza Group
  • InSphero AG
  • Merck KGaA
  • Thermo Fisher Scientific Inc.
  • Corning Incorporated
  • Prellis Biologics
  • Collagen Solutions (US) LLC
  • SunP BIOTECH
  • Cellink

第 12 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 13 章：附录

简介目录
Product Code: BT6742

The global tissue engineering market reached US$ 18.9 billion in 2024 and is expected to reach US$ 65.1 billion by 2033, growing at a CAGR of 14.9% during the forecast period 2025-2033.

Tissue engineering is an important tool in understanding how certain conditions progress and how they can be treated. It is part of the field of bioengineering, a broad discipline that combines principles from biology and engineering. Bioengineering is sometimes described as taking an engineering approach to the study of biology. Tissue engineering involves investigating the biological, physical, and chemical forces involved in tissue development, injury, and wound healing.

The goal of tissue engineering is to fabricate functional tissues and organs that can integrate seamlessly with the patient's body, ultimately improving patient outcomes and quality of life. This field encompasses various approaches, including scaffold-based techniques, cell-based therapies and bioactive molecule delivery systems.

The tissue engineering market is experiencing consistent growth with advancements in the field of tissue engineering and rising funding for tissue engineering. For instance, in November 2023, SPRIND Funke Tissue Engineering launched a ten-month journey to explore and demonstrate the key characteristics of artificial tissue embarking with four ambitious teams. SPRIND provided up to EUR 500,000 in funding to support this groundbreaking work.

Market Dynamics: Drivers & Restraints

Rising prevalence of chronic diseases

The rising prevalence of chronic diseases is significantly driving the growth of the tissue engineering market and is expected to drive the market over the forecast period. As chronic diseases such as diabetes, cardiovascular diseases, osteoarthritis and kidney disorders increase globally, the need for advanced treatment options, including tissue engineering, has grown.

For instance, according to the WHO, an estimated 17.9 million people die from cardiovascular diseases (CVDs) each year, making them the world's leading cause of mortality. The bulk of the 422 million individuals with diabetes globally reside in low- and middle-income nations, and the disease is directly responsible for 1.5 million fatalities annually. Around 1.71 billion people worldwide suffer from musculoskeletal disorders. The need for tissue engineering is expected to rise as a result of the rising incidence of numerous chronic illnesses.

Chronic diseases often lead to tissue damage or degeneration that traditional treatments cannot fully repair. Tissue engineering offers solutions by creating replacement tissues or organs, aiding in healing and regeneration. For instance, diabetic patients suffer from poor wound healing, necessitating tissue engineering for skin or vascular repair.

Additionally, developments in brain, lung, liver, and bone tissue engineering are useful for creating in vitro models of cancer metastasis. Because tissue engineering offers ways to directly examine carcinogenesis and migration at metastases, it has the potential to revolutionize cancer research. Since inducing angiogenesis is a key characteristic of cancer, neovascularization is frequently linked to the formation of solid tumors. Additionally, tissue engineering makes it possible to replicate the tumor microenvironment and all of its intricate and multifaceted features. Thus, rising cancer cases boosts the demand for tissue engineering.

High cost associated with the tissue engineering technique

The high cost associated with tissue engineering techniques is one of the major factors hampering the growth of the tissue engineering market. While tissue engineering holds promise for addressing chronic diseases and tissue damage, the costs involved in its development, production, and implementation are significant. For instance, according to the National Institute of Health (NIH), the total costs of stem cell-based tissue-engineered airway transplants for the three UK patients treated ranged from $174,420 to $740,500.

The development of bioprinted tissues using 3D printing technology is highly cost-intensive due to the need for specialized bioprinting machines, advanced biomaterials, and skilled technicians. While it holds significant potential, this technology is not yet affordable for widespread use. For instance, according to ResearchGate, bioprinting techniques prices range from $5,000 to over $500,000.

Segment Analysis

The global tissue engineering market is segmented based on material type, technology, application, end-user and region.

Technology:

The biomaterials and scaffolds segment is expected to dominate the tissue engineering market share

Biomaterials and scaffolds serve as the foundation for tissue regeneration by providing structural support for growing cells and promoting tissue formation. Biomaterials interact with biological systems to promote desired therapeutic outcomes, such as tissue regeneration, repair or replacement. In tissue engineering, biomaterials serve as scaffolds, carriers or matrices for cells and bioactive molecules, providing a supportive environment for tissue formation and integration. Thus, biomaterials and scaffolds are highly used for many research activities.

For instance, in November 2023, To conduct the research, Dr. ZHAO combined several disciplines, including material science, cell biology, engineering, and medicine. Her research focuses on modifying cell microenvironments, influencing cell behaviors, and promoting the growth of tissue-engineered organs. Her research team actively studies how cells perceive, interact, and evolve with biomaterials to restore diseased or damaged tissues to create patient-oriented biomaterials with distinctive shapes and properties.

Biomaterials serve as carriers for bioactive molecules, therapeutic agents or cells in tissue engineering applications. These biomaterials are used in bioprinting and pharmaceutical drug development. For instance, in September 2022, 3D Systems established Systemic Bio, a new, fully owned business. Systemic Bio will use biomaterials and human cells to produce incredibly accurate vascularized organ models by utilizing 3D Systems' innovative, production-level bioprinting technology. At the very beginning of the creation of new pharmaceutical drugs, these unique organs-on-chips can be produced in huge quantities with reproducible results and then perfused with any desired drug molecule to research drug metabolism and its effects on healthy or sick tissue.

Geographical Analysis

North America is expected to hold a significant position in the tissue engineering market share

North America is home to many leading companies in the tissue engineering space, which drive innovation and commercialization. These companies are involved in developing biomaterials, scaffolds, and cell-based therapies for various applications, including orthopedics, cardiovascular diseases, and wound healing.

Companies like Organovo, a leader in 3D bioprinting, Medtronic and other emerging players that develop advanced tissue engineering solutions, have strong presences in North America. The presence of these market leaders fosters a competitive environment that accelerates market growth.

For instance, in August 2024, CytoNest Inc. launched its first commercial product, a fiber scaffold that enhances tissue engineering and cell production. Applications for the product, known as CytoSurge 3D fiber scaffold, include cell research, biopharmaceutical cell therapies and the generation of cultured meat and seafood.

Asia-Pacific is growing at the fastest pace in the tissue engineering market

Tissue engineering in the Asia-Pacific region is expanding from research into clinical applications, with several companies and research institutions moving toward commercialization. The clinical application of tissue engineering technologies such as 3D bioprinting helps in treating conditions like skin burns, bone fractures, cartilage damage, organ failure and others are gaining momentum.

For instance, in November 2024, Scire Science, a biotech company based in Kochi, made history by introducing India's first patented domestic bioink for sophisticated 3D bioprinting applications. This invention positions Scire Science as an Indian leader in a field dominated by a small number of multinational corporations. With the use of sophisticated 3D bioprinting, this technique makes it possible to biofabricate the tissues of the liver, kidney, pancreas, skin, brain and heart.

Competitive Landscape

The major global players in the tissue engineering market include 3D BioFibR Inc., CollPlant Biotechnologies Ltd, Lonza Group, InSphero AG, Merck KGaA, Thermo Fisher Scientific Inc., Corning Incorporated, Prellis Biologics, Collagen Solutions (US) LLC, SunP BIOTECH, Cellink and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global tissue engineering market report delivers a detailed analysis with 73 key tables, more than 70 visually impactful figures, and 197 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Material Type
  • 2.4. Snippet by Technology
  • 2.5. Snippet by Application
  • 2.6. Snippet by End-User
  • 2.7. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Prevalence of Chronic Diseases
    • 3.1.2. Restraints
      • 3.1.2.1. High Cost Associated with the Tissue Engineering Technique
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Force Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. SWOT Analysis
  • 4.9. Unmet Needs and Gaps
  • 4.10. Recommended Strategies for Market Entry and Expansion
  • 4.11. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.12. Pricing Analysis and Price Dynamics

5. Tissue Engineering Market, By Material Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 5.1.2. Market Attractiveness Index, By Material Type
  • 5.2. Synthetic Materials*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. Polymers
    • 5.2.4. Hydrogels
    • 5.2.5. Ceramics
    • 5.2.6. Composites
  • 5.3. Natural Materials
    • 5.3.1. Extracellular Matrix (ECM) Proteins
    • 5.3.2. Fibrin
    • 5.3.3. Collagen
    • 5.3.4. Silk
  • 5.4. Nanofiber Scaffolds
  • 5.5. Protein-Based Materials
  • 5.6. Others

6. Tissue Engineering Market, By Technology

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 6.1.2. Market Attractiveness Index, By Technology
  • 6.2. Biomaterials and Scaffolds*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Cell Culture
  • 6.4. Bioreactors and Culture Systems
  • 6.5. Bio-printing
  • 6.6. Others

7. Tissue Engineering Market, By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Musculoskeletal*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Skin & Integumentary
  • 7.4. Cardiology
  • 7.5. Neurology
  • 7.6. Others

8. Tissue Engineering Market, By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Hospitals and Clinics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Contract Development and Manufacturing Organization
  • 8.4. Research and Academic Institutes
  • 8.5. Biotechnology and Pharmaceutical Companies

9. Tissue Engineering Market, By Regional Market Analysis and Growth Opportunities

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.7.1. U.S.
      • 9.2.7.2. Canada
      • 9.2.7.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.7.1. Germany
      • 9.3.7.2. U.K.
      • 9.3.7.3. France
      • 9.3.7.4. Spain
      • 9.3.7.5. Italy
      • 9.3.7.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.7.1. Brazil
      • 9.4.7.2. Argentina
      • 9.4.7.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.7.1. China
      • 9.5.7.2. India
      • 9.5.7.3. Japan
      • 9.5.7.4. South Korea
      • 9.5.7.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape and Market Positioning

  • 10.1. Competitive Overview and Key Market Players
  • 10.2. Market Share Analysis and Positioning Matrix
  • 10.3. Strategic Partnerships, Mergers & Acquisitions
  • 10.4. Key Developments in Product Portfolios and Innovations
  • 10.5. Company Benchmarking

11. Company Profiles

  • 11.1. 3D BioFibR Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
    • 11.1.5. SWOT Analysis
  • 11.2. CollPlant Biotechnologies Ltd.
  • 11.3. Lonza Group
  • 11.4. InSphero AG
  • 11.5. Merck KGaA
  • 11.6. Thermo Fisher Scientific Inc.
  • 11.7. Corning Incorporated
  • 11.8. Prellis Biologics
  • 11.9. Collagen Solutions (US) LLC
  • 11.10. SunP BIOTECH
  • 11.11. Cellink

LIST NOT EXHAUSTIVE

12. Assumption and Research Methodology

  • 12.1. Data Collection Methods
  • 12.2. Data Triangulation
  • 12.3. Forecasting Techniques
  • 12.4. Data Verification and Validation

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us